D57.412
Sickle-cell thalassemia, unspecified, with splenic sequestration
Clinical Classification Guidelines
Medical Intelligence & Overview
Sickle-cell thalassemia with splenic sequestration, coded as D57.412 in the ICD-10 classification, is a rare but serious blood disorder that combines elements of both sickle-cell disease and thalassemia. It involves abnormal hemoglobin production, leading to distorted red blood cells that can cause blockages and hemolytic anemia. The condition's unique feature, splenic sequestration, refers to the sudden pooling of sickled red blood cells in the spleen, which can cause rapid enlargement of the organ and potentially life-threatening complications if not promptly managed.
Causes & Symptoms
Clinical Causes: Inherited genetic mutations affecting hemoglobin production Autosomal recessive inheritance pattern Presence of genes for sickle hemoglobin (HbS) and thalassemia Genetic predisposition common in populations from Africa, the Mediterranean, the Middle East, and Asia
Key Symptoms: Sudden and rapid enlargement of the spleen Anemia symptoms such as fatigue, weakness, and pallor Episodes of pain, especially in the abdomen or chest Fever and signs of infection Paleness or jaundice due to increased breakdown of red blood cells Shortness of breath and rapid heartbeat Symptoms of hypovolemic shock if significant blood loss occurs during sequestration episodes
Diagnostic & Treatment
Diagnosis Path: Diagnosis involves a combination of laboratory tests and clinical evaluation. Blood tests reveal abnormal hemoglobin types, low hemoglobin levels, and elevated reticulocyte counts. Hemoglobin electrophoresis confirms the presence of sickle hemoglobin and thalassemia traits. Imaging studies like ultrasound or CT scans help assess spleen size and detect sequestration episodes. Genetic testing may identify specific mutations contributing to the condition.
Treatment Protocols: Managing sickle-cell thalassemia with splenic sequestration focuses on preventing and treating complications. Key approaches include: - **Blood transfusions:** Regular or as-needed transfusions to reduce the number of sickled cells and manage anemia. - **Hydroxyurea therapy:** A medication that can decrease the frequency of sickling episodes. - **Splenectomy:** Surgical removal of the spleen may be considered in recurrent or severe sequestration episodes. - **Pain management:** Treating vaso-occlusive pain episodes with analgesics. - **Infection prevention:** Vaccinations and prophylactic antibiotics to reduce infection risk, as the spleen plays a crucial role in fighting bacteria. - **Monitoring and supportive care:** Regular follow-up to monitor blood counts, spleen size, and overall health status. The treatment plan should always be tailored to each individual's specific needs and complications, with close coordination among healthcare providers.
Clinical Advice & FAQs
Billing Guidance
Is D57.412 a billable ICD-10 code?
Yes, D57.412 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D57.412?
Clinical documentation must specify the nature of Sickle-cell thalassemia, unspecified, with splenic sequestration and any associated comorbidities for accurate reporting.
Cite this Clinical Reference